# A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel Disease

> **NCT03466983** · PHASE4 · COMPLETED · sponsor: **Pharmacosmos A/S** · enrollment: 97 (actual)

## Conditions studied

- IBD

## Interventions

- **DRUG:** Iron Isomaltoside
- **DRUG:** Ferric Carboxymaltose

## Key facts

- **NCT ID:** NCT03466983
- **Lead sponsor:** Pharmacosmos A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-23
- **Primary completion:** 2020-05-25
- **Final completion:** 2020-05-25
- **Target enrollment:** 97 (ACTUAL)
- **Last updated:** 2021-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03466983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03466983, "A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel Disease". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03466983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*